Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.26
- Piotroski Score 3.00
- Grade N/A
- Symbol (BIOS)
- Company BioPlus Acquisition Corp.
- Price $10.80
- Changes Percentage (-0.05%)
- Change -$0.01
- Day Low $10.79
- Day High $10.80
- Year High $11.68
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/30/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.21
- Trailing P/E Ratio 51.404761904762
- Forward P/E Ratio 51.404761904762
- P/E Growth 51.404761904762
- Net Income $5.16 M
Income Statement
Quarterly
Annual
Latest News of BIOS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
9 investors hold a 53% majority stake in Sagimet Biosciences Inc. (NASDAQ: SGMT). Institutional investors have the largest ownership at 40%, impacting market cap fluctuations. Analysts' forecasts and ...
By Yahoo! Finance | 10 hours ago -
Avid Bioservices, Inc. (CDMO): A Bull Case Theory
Avid Bioservices, Inc. (CDMO) is expected to see significant growth in the biopharmaceutical industry due to market trends and legislative changes. The company's strategic position, cutting-edge facil...
By Yahoo! Finance | 22 hours ago -
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares
Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Vikin...
By Yahoo! Finance | 1 day ago
